Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Interest Expenses (2016 - 2025)

Cytokinetics (CYTK) has disclosed Interest Expenses for 12 consecutive years, with $18.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest Expenses changed N/A to $18.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $40.9 million, a N/A change, with the full-year FY2025 number at $45.6 million, up 20.9% from a year prior.
  • Interest Expenses was $18.5 million for Q4 2025 at Cytokinetics, up from $11.4 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $18.5 million in Q4 2025 to a low of $2.7 million in Q1 2022.
  • A 5-year average of $7.4 million and a median of $7.1 million in 2022 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: crashed 31.14% in 2022, then soared 153.5% in 2023.
  • Cytokinetics' Interest Expenses stood at $4.2 million in 2021, then surged by 67.31% to $7.1 million in 2022, then rose by 1.52% to $7.2 million in 2023, then grew by 24.62% to $8.9 million in 2024, then soared by 106.81% to $18.5 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Interest Expenses are $18.5 million (Q4 2025), $11.4 million (Q3 2025), and $11.1 million (Q2 2025).